Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil falls 3% to one-week low as supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
August 13, 2024 6:54 AM EDTOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $28.00 price target on Adverum Biotechnologies (NASDAQ: ADVM).
The analyst comments "ADVM reported its 2Q24 with EPS coming in at ($0.89), beating both our estimated ($1.25) and Street's ($1.47)E. As ADVM continues to focus on the... More
H.C. Wainwright Reiterates Buy Rating on Adverum Biotechnologies (ADVM)
August 13, 2024 6:11 AM EDTH.C. Wainwright analyst Matt Caufield reiterated a Buy rating and $30.00 price target on Adverum Biotechnologies (NASDAQ: ADVM)
The analyst comments "Anticipating 9-month support for injection benefit and safety. We believe the most important near-term catalyst, for wet AMD single-injection intravitreal (IVT) gene therapy candidate Ixo-vec, is the anticipated 4Q24 landmark 9-month analysis from the ongoing Phase 2 LUNA trial of Ixo-vec in wet AMD. While appreciating the full 52-week... More
